European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 144, Issue 1 , Pages 48-53 , May 2009

Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas—A pilot study

  • Kristine Lossl

      Affiliations

    • The Fertility Clinic Section 4071, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
    • Corresponding Author InformationCorresponding author.
    • ,
  • Anne Loft

      Affiliations

    • The Fertility Clinic Section 4071, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
    • ,
  • Nina L.C. Freiesleben

      Affiliations

    • The Fertility Clinic Section 4071, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
    • ,
  • Susanne Bangsbøll

      Affiliations

    • The Fertility Clinic Section 4071, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
    • ,
  • Claus Yding Andersen

      Affiliations

    • Laboratory of Reproductive Biology Section 5712, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
    • ,
  • Anette T. Pedersen

      Affiliations

    • Department of Obstetrics and Gynaecology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
    • ,
  • Dorthe Hartwell

      Affiliations

    • Department of Obstetrics and Gynaecology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
    • ,
  • Anders Nyboe Andersen

      Affiliations

    • The Fertility Clinic Section 4071, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Received 23 September 2008 ,Revised 29 November 2008 ,Accepted 1 February 2009.

References 

  1. Barnhart K, Dunsmoor-Su R, Coutifaris C. Effect of endometriosis on in vitro fertilization. Fertil Steril. 2002;77(June (6)):1148–1155
  2. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997;67(May (5)):817–21.
  3. Tsoumpou I, Kyrgiou M, Gelbaya TA, Nardo LG. The effect of surgical treatment for endometrioma on in vitro fertilization outcomes: a systematic review and meta-analysis. Fertil Steril. August 2008;
  4. Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis?. Fertil Steril. 2006;85(May (5)):1307–1318
  5. Lonning PE, Geisler J, Bhatnager A. Development of aromatase inhibitors and their pharmacologic profile. Am J Clin Oncol. 2003;26(August (4)):S3–S8
  6. Sallam HN, Garcia-Velasco JA, Dias S, Arici A. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev. 2006;(1):CD004635
  7. Batioglu S, Celikkanat H, Ugur M, Mollamahmutoglu L, Yesilyurt H, Kundakci M. The use of GnRH-agonists in the treatment of endometriomas with or without drainage. J Pak Med Assoc. 1996;46(February (2)):30–32
  8. Takeuchi H, Kobori H, Kikuchi I, Sato Y, Mitsuhashi N. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH-agonists in cases of uterine leiomyomas or endometriosis. J Obstet Gynaecol Res. 2000;26(October (5)):325–331
  9. Donnez J, Nisolle-Pochet M, Clerckx-Braun F, Sandow J, Casanas-Roux F. Administration of nasal Buserelin as compared with subcutaneous Buserelin implant for endometriosis. Fertil Steril. 1989;52(July (1)):27–30
  10. Rana N, Thomas S, Rotman C, Dmowski WP. Decrease in the size of ovarian endometriomas during ovarian suppression in stage IV endometriosis. Role of preoperative medical treatment. J Reprod Med. 1996;41(June (6)):384–392
  11. Takahashi K, Okada S, Okada M, Kitao M, Imaoka I, Sugimura K. Prognostic application of magnetic resonance imaging in patients with endometriomas treated with gonadotrophin-releasing hormone analogue. Hum Reprod. 1996;11(May (5)):1083–1085
  12. Ozaksit G, Caglar T, Cicek N, Kuscu E, Batioglu S, Gokmen O. Serum CA 125 levels before, during and after treatment for endometriosis. Int J Gynaecol Obstet. 1995;50(September (3)):269–273
  13. Kafali H, Artuc H, Demir N. Use of CA125 fluctuation during the menstrual cycle as a tool in the clinical diagnosis of endometriosis; a preliminary report. Eur J Obstet Gynecol Reprod Biol. 2004;116(September (1)):85–88
  14. Soysal S, Soysal ME, Ozer S, Gul N, Gezgin T. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod. 2004;19(January (1)):160–167
  15. Garcia-Velasco JA, Mahutte NG, Corona J, et al. Removal of endometriomas before in vitro fertilization does not improve fertility outcomes: a matched, case–control study. Fertil Steril. 2004;81(May (5)):1194–1197
  16. Lossl K, Andersen AN, Loft A, Freiesleben NL, Bangsboll S, Andersen CY. Androgen priming using aromatase inhibitor and hCG during early-follicular-phase GnRH antagonist down-regulation in modified antagonist protocols. Hum Reprod. 2006;21(October (10)):2593–2600
  17. Lossl K, Andersen CY, Loft A, Freiesleben NL, Bangsboll S, Andersen AN. Short-term androgen priming by use of aromatase inhibitor and hCG before controlled ovarian stimulation for IVF. A randomized controlled trial. Hum Reprod. 2008;23(August (8)):1820–1829
  18. Andersen CY. Characteristics of human follicular fluid associated with successful conception after in vitro fertilization. J Clin Endocrinol Metab. 1993;77(November (5)):1227–1234
  19. McNatty KP, Smith DM, Makris A, Osathanondh R, Ryan KJ. The microenvironment of the human antral follicle: interrelationships among the steroid levels in antral fluid, the population of granulosa cells, and the status of the oocyte in vivo and in vitro. J Clin Endocrinol Metab. 1979;49(December (6)):851–860
  20. Lonning P, Pfister C, Martoni A, Zamagni C. Pharmacokinetics of third-generation aromatase inhibitors. Semin Oncol. 2003;30(August (4 Suppl. 14)):23–32
  21. Fleming R, Lloyd F, Herbert M, Fenwick J, Griffiths T, Murdoch A. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod. 1998;13(July (7)):1788–1792
  22. Nyboe Andersen A, Humaidan P, Fried G, Hausken J, Antila L, Bangsboll S. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. Hum Reprod. 2008;23(February (2)):427–434
  23. Westergaard LG, Erb K, Laursen SB, Rex S, Rasmussen PE. Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study. Fertil Steril. 2001;76(September (3)):543–549
  24. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod. 2000;15(May (5)):1003–1008
  25. Rickes D, Nickel I, Kropf S, Kleinstein J. Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertil Steril. 2002;78(October (4)):757–762
  26. Moore J, Copley S, Morris J, Lindsell D, Golding S, Kennedy S. A systematic review of the accuracy of ultrasound in the diagnosis of endometriosis. Ultrasound Obstet Gynecol. 2002;20(December (6)):630–634
  27. Patel MD, Feldstein VA, Chen DC, Lipson SD, Filly RA. Endometriomas: diagnostic performance of US. Radiology. 1999;210(March (3)):739–745

PII: S0301-2115(09)00086-4

doi: 10.1016/j.ejogrb.2009.02.001

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 144, Issue 1 , Pages 48-53 , May 2009

Article Tools

* Image Usage & Resolution